Postpartum thyroiditis risk factors: Difference between revisions
Jump to navigation
Jump to search
Sunny Kumar (talk | contribs) |
Usama Talib (talk | contribs) No edit summary |
||
| (11 intermediate revisions by 3 users not shown) | |||
| Line 2: | Line 2: | ||
{{Postpartum thyroiditis}} | {{Postpartum thyroiditis}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{SKA}} | ||
==Overview== | ==Overview== | ||
The most potent risk | The most potent risk factors in the development of [[Postpartum thyroiditis|postpartum thyroiditis (PPT)]] are [[Genetics|genetic]] abnormalities and subsequent pregnancies. Other risk factors for postpartum thyroiditis include [[smoking]], increase or decreased intake of [[iodine]], [[hepatitis C]], [[Radiation exposure|radiations]] and [[medications]]. | ||
==Risk Factors== | ==Risk Factors== | ||
Various factors associated with the development of PPT can be categorized into common and less common risk factors.<ref name="pmid25507668">{{cite journal| author=Argatska AB, Nonchev BI| title=Postpartum thyroiditis. | journal=Folia Med (Plovdiv) | year= 2014 | volume= 56 | issue= 3 | pages= 145-51 | pmid=25507668 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25507668 }}</ref> | |||
===Common Risk Factors=== | ===Common Risk Factors=== | ||
*Common risk | *Common risk factors in the development of [[Postpartum thyroiditis|PPT]] is [[Genetics|genetic]] abnormalities in: | ||
**CD60 CTLA-4 gene | **CD60 CTLA-4 [[gene]] | ||
**HLA DR3 | **[[HLA DR3-DQ2|HLA DR3]] haplotype | ||
**HLA DR4 | **[[HLA-DR4|HLA DR4]] haplotype | ||
**HLA DR5 | **HLA [[HLA-DR5|DR5]] haplotype | ||
* Subsequent pregnancies are also a common risk factor for the development of postpartum thyroiditis. | |||
===Less Common Risk Factors=== | ===Less Common Risk Factors=== | ||
*Less common risk factors in the development of PPT | *Less common risk factors in the development of postpartum thyroiditis ([[Postpartum thyroiditis|PPT]]) include: | ||
* | *#[[Smoking]] | ||
* | *#Intake of [[Iodine]] | ||
* | *#[[Radiation]] | ||
* | *#Medications: | ||
* | *#*[[Lithium]] | ||
* | *#*[[Amiodarone]] | ||
* | *#*[[Interferon alpha|Interferon alpha]] | ||
*#*[[Interleukin 2]] | |||
*#*Highly active [[HIV AIDS medical therapy|anti-retro-viral therapy]] | |||
*#[[Systemic lupus erythematosus|Systemic lupus erythromatosis]] | |||
*#[[Multiple Sclerosis]] | |||
*#[[Thyroid]] hormone resistance syndrome | |||
==References== | ==References== | ||
{{WH}} | |||
{{WS}} | {{WS}} | ||
[[Category: (name of the system)]] | [[Category: (name of the system)]] | ||
<references /> | |||
Latest revision as of 14:59, 10 November 2017
|
Postpartum thyroiditis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Postpartum thyroiditis risk factors On the Web |
|
American Roentgen Ray Society Images of Postpartum thyroiditis risk factors |
|
Risk calculators and risk factors for Postpartum thyroiditis risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sunny Kumar MD [2]
Overview
The most potent risk factors in the development of postpartum thyroiditis (PPT) are genetic abnormalities and subsequent pregnancies. Other risk factors for postpartum thyroiditis include smoking, increase or decreased intake of iodine, hepatitis C, radiations and medications.
Risk Factors
Various factors associated with the development of PPT can be categorized into common and less common risk factors.[1]
Common Risk Factors
- Subsequent pregnancies are also a common risk factor for the development of postpartum thyroiditis.
Less Common Risk Factors
- Less common risk factors in the development of postpartum thyroiditis (PPT) include:
- Smoking
- Intake of Iodine
- Radiation
- Medications:
- Lithium
- Amiodarone
- Interferon alpha
- Interleukin 2
- Highly active anti-retro-viral therapy
- Systemic lupus erythromatosis
- Multiple Sclerosis
- Thyroid hormone resistance syndrome
References
- ↑ Argatska AB, Nonchev BI (2014). "Postpartum thyroiditis". Folia Med (Plovdiv). 56 (3): 145–51. PMID 25507668.